Skip to main content

Publications

What type of publication do you want to show?

2024

Favipiravir pharmacokinetics in Thai adults with mild <scp>COVID</scp>‐19: A sub‐study of interpatient variability and ethnic differences in exposure

Prasanchaimontri, I., Manosuthi, W., Pertinez, H., Owen, A., Niyomnaitham, S., Sirijatuphat, R., . . . Chokephaibulkit, K. (2024). Favipiravir pharmacokinetics in Thai adults with mild <scp>COVID</scp>‐19: A sub‐study of interpatient variability and ethnic differences in exposure. Pharmacology Research &amp; Perspectives, 12(6). doi:10.1002/prp2.1233

DOI
10.1002/prp2.1233
Journal article

Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.

Kawano-Dourado, L., Kristianslund, E. K., Zeraatkar, D., Jani, M., Makharia, G., Hazlewood, G., . . . Vandvik, P. O. (2024). Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.. BMJ (Clinical research ed.), 387, e079830. doi:10.1136/bmj-2024-079830

DOI
10.1136/bmj-2024-079830
Journal article

The long wait for long-acting HIV prevention and treatment formulations.

Venter, W. D. F., Gandhi, M., Sokhela, S., Sikwese, K., Bygrave, H., Gama, L. D., . . . Hill, A. (2024). The long wait for long-acting HIV prevention and treatment formulations.. The lancet. HIV, 11(10), e711-e716. doi:10.1016/s2352-3018(24)00173-5

DOI
10.1016/s2352-3018(24)00173-5
Journal article

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.

Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., . . . Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.. Microbiology spectrum, 12(8), e0391623. doi:10.1128/spectrum.03916-23

DOI
10.1128/spectrum.03916-23
Journal article

Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.

Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232

DOI
10.1093/jac/dkae232
Journal article

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19

DOI
10.1101/2024.02.27.582110
Preprint

Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.

Clark, J. J., Penrice-Randal, R., Sharma, P., Dong, X., Pennington, S. H., Marriott, A. E., . . . Stewart, J. P. (2024). Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.. Viruses, 16(6), 863. doi:10.3390/v16060863

DOI
10.3390/v16060863
Journal article

Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.

Gupta, N., Swindells, S., Scarsi, K. K., Furl, R., Thomas, D. L., Weld, E. D., . . . Ward, J. W. (2024). Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.. Journal of viral hepatitis, 31(5), 221-232. doi:10.1111/jvh.13921

DOI
10.1111/jvh.13921
Journal article

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.

DOI
10.1101/2024.03.03.583160
Preprint

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using LC-MS/MS

DOI
10.22541/au.170667560.03045745/v1
Preprint

2023

Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.

Liu, C., Hern, F. Y., Shakil, A., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2023). Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.. Journal of materials chemistry. B, 11(48), 11532-11543. doi:10.1039/d3tb02268d

DOI
10.1039/d3tb02268d
Journal article

Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration

Morris, S., Long, M., Savage, A., Owen, A., Rannard, S., & Cauldbeck, H. (n.d.). Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration. Nanoscale Advances. doi:10.1039/d3na00454f

DOI
10.1039/d3na00454f
Journal article

The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections

De Neck, S., Penrice-Randal, R., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., . . . Kipar, A. (2023). The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses, 15(8), 1637. doi:10.3390/v15081637

DOI
10.3390/v15081637
Journal article

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy

Chang, Y. S., Li, S. -Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S. P., . . . Ammerman, N. C. (2023). Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 67(7). doi:10.1128/aac.00481-23

DOI
10.1128/aac.00481-23
Journal article

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022)

Smith, T. A., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2023). Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022). TRIALS, 24(1). doi:10.1186/s13063-023-07364-3

DOI
10.1186/s13063-023-07364-3
Journal article

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy.

DOI
10.1101/2023.04.12.536604
Preprint

Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.

BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2

DOI
10.1186/s12981-023-00514-2
Journal article

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.

DOI
10.1101/2022.01.23.477397
Preprint

Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.

Cirrincione, L. R., Nakalema, S., Chappell, C. A., Byakika-Kibwika, P., Kyohairwe, I., Winchester, L., . . . Scarsi, K. K. (2023). Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.. Contraception, 109975. doi:10.1016/j.contraception.2023.109975

DOI
10.1016/j.contraception.2023.109975
Journal article

Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes.

Balta, V. A., Stiffler, D., Sayeed, A., Tripathi, A. K., Elahi, R., Mlambo, G., . . . Shapiro, T. A. (2023). Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes.. bioRxiv. doi:10.1101/2023.02.07.527535

DOI
10.1101/2023.02.07.527535
Journal article

Chasing COVID-19 chemotherapeutics without putting the cart before the horse

Rannard, S. P., McDonald, T. O., & Owen, A. (2023). Chasing COVID-19 chemotherapeutics without putting the cart before the horse. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 89(1), 421-423. doi:10.1111/bcp.14575

DOI
10.1111/bcp.14575
Journal article

Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

Gurjar, R., Dickinson, L., Carr, D., Stohr, W., Bonora, S., Owen, A., . . . Boffito, M. (2022). Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. PHARMACOGENOMICS JOURNAL. doi:10.1038/s41397-022-00293-5

DOI
10.1038/s41397-022-00293-5
Journal article

2022

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K. K., Charoenpong, L., . . . Chokephaibulkit, K. (2022). Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. EMERGING MICROBES & INFECTIONS, 11(1), 2197-2206. doi:10.1080/22221751.2022.2117092

DOI
10.1080/22221751.2022.2117092
Journal article

WHO Living Guidelines on antivirals for COVID-19 are evidence-based

Owen, A., Diaz, J. V., Guyatt, G., Lamontagne, F., Stegemann, M., Vandvik, P. O., & Agoritsas, T. (2022). WHO Living Guidelines on antivirals for COVID-19 are evidence-based. LANCET, 400(10369), 2196-2198. doi:10.1016/S0140-6736(22)02306-6

DOI
10.1016/S0140-6736(22)02306-6
Journal article

Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., . . . Venter, W. D. F. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBIOMEDICINE, 86. doi:10.1016/j.ebiom.2022.104322

DOI
10.1016/j.ebiom.2022.104322
Journal article

Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment

Ammerman, N. C., Nuermberger, E. L., Owen, A., Rannard, S. P., Meyers, C. F., & Swindells, S. (2022). Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment. CLINICAL INFECTIOUS DISEASES, 75, S510-S516. doi:10.1093/cid/ciac672

DOI
10.1093/cid/ciac672
Journal article

Prospects for Long-Acting Treatments for Hepatitis C

Thomas, D. L., Owen, A., & Kiser, J. J. (2022). Prospects for Long-Acting Treatments for Hepatitis C. CLINICAL INFECTIOUS DISEASES, 75, S525-S529. doi:10.1093/cid/ciac715

DOI
10.1093/cid/ciac715
Journal article

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. (2022). The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. CLINICAL INFECTIOUS DISEASES, 75, S502-S509. doi:10.1093/cid/ciac750

DOI
10.1093/cid/ciac750
Journal article

Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Hentzien, M., Owen, A., Strub-Wourgaft, N., Perez-Casas, C., Troseid, M., & Calmy, A. (2022). Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. FRONTIERS IN MICROBIOLOGY, 13. doi:10.3389/fmicb.2022.998287

DOI
10.3389/fmicb.2022.998287
Journal article

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

Weld, E. D., Astemborski, J., Kirk, G. D., Sulkowski, M. S., Katz, S., Rothman, R., . . . Thomas, D. L. (2022). Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. CLINICAL INFECTIOUS DISEASES, 75(1), 3-10. doi:10.1093/cid/ciab913

DOI
10.1093/cid/ciab913
Journal article

Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Smith, T., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2022). Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). TRIALS, 23(1). doi:10.1186/s13063-022-06533-0

DOI
10.1186/s13063-022-06533-0
Journal article

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria

Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3

DOI
10.1186/s12981-022-00462-3
Journal article

Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants

Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825d

DOI
10.1039/d2tb00825d
Journal article

Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).

DOI
10.21203/rs.3.rs-1273552/v1
Preprint

Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study

DOI
10.1101/2022.06.06.22275902
Preprint

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.

DOI
10.1101/2022.03.03.482788
Preprint

Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2

Jeffreys, L. N., Pennington, S. H., Duggan, J., Caygill, C. H., Lopeman, R. C., Breen, A. F., . . . Biagini, G. A. (2022). Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 59(3). doi:10.1016/j.ijantimicag.2022.106542

DOI
10.1016/j.ijantimicag.2022.106542
Journal article

Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19

DOI
10.1101/2022.02.03.22270152
Preprint

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Quinn, T. M., Gaughan, E. E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., . . . Dhaliwal, K. (2022). Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBIOMEDICINE, 76. doi:10.1016/j.ebiom.2022.103856

DOI
10.1016/j.ebiom.2022.103856
Journal article

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

DOI
10.12688/wellcomeopenres.17202.3
Preprint

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.

Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2

DOI
10.12688/wellcomeopenres.17202.2
Journal article

2021

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318

DOI
10.1093/jac/dkab318
Journal article

Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics

DOI
10.1101/2021.10.06.21264648
Preprint

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1

DOI
10.12688/wellcomeopenres.17202.1
Journal article

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

DOI
10.1101/2021.09.10.21263376
Preprint

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4

DOI
10.1186/s13063-021-05458-4
Journal article

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

DOI
10.21203/rs.3.rs-548968/v1
Preprint

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants

DOI
10.1101/2021.07.21.451321
Preprint

<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Sacramento, C. Q., Fintelman-Rodrigues, N., Temerozo, J. R., Dias Da Silva, A. D. P., Gomes Dias, S. D. S., da Silva, C. D. S., . . . Souza, T. M. L. (2021). <i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(7), 1874-1885. doi:10.1093/jac/dkab072

DOI
10.1093/jac/dkab072
Journal article

Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?

Stachulski, A. V., Taujanskas, J., Pate, S. L., Rajoli, R. K. R., Aljayyoussi, G., Pennington, S. H., . . . O'Neill, P. M. (2021). Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS INFECTIOUS DISEASES, 7(6), 1317-1331. doi:10.1021/acsinfecdis.0c00478

DOI
10.1021/acsinfecdis.0c00478
Journal article

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

DOI
10.1101/2021.05.03.21256309
Preprint

A living WHO guideline on drugs to prevent covid-19

Lamontagne, F., Agoritsas, T., Siemieniuk, R., Rochwerg, B., Bartoszko, J., Askie, L., . . . Jacobs, M. (2021). A living WHO guideline on drugs to prevent covid-19. BMJ-BRITISH MEDICAL JOURNAL, 372. doi:10.1136/bmj.n526

DOI
10.1136/bmj.n526
Journal article

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.

Pertinez, H., Rajoli, R. K., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.. medRxiv. doi:10.1101/2021.01.03.21249159

DOI
10.1101/2021.01.03.21249159
Journal article

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

Olagunju, A., Fowotade, A., Olagunoye, A., Ojo, T. O., Adefuye, B. O., Fagbamigbe, A. F., . . . Owen, A. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 22(1). doi:10.1186/s13063-020-04987-8

DOI
10.1186/s13063-020-04987-8
Journal article

Long-acting drugs and formulations for the treatment and prevention of HIV infection

Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(1). doi:10.1016/j.ijantimicag.2020.106220

DOI
10.1016/j.ijantimicag.2020.106220
Journal article

Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events

Hoffmann, C., MacKay, A., Schewe, C. K., Hansen, S., Buhk, T., Fenske, S., . . . Elliot, E. (2021). Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events. In INFECTION Vol. 49 (pp. S21-S22). Retrieved from https://www.webofscience.com/

Conference Paper

2020

Remdesivir-ivermectin combination displays synergistic interaction with improved<i>in vitro</i>antiviral activity against SARS-CoV-2

DOI
10.1101/2020.12.23.424232
Preprint

Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19

Clark, J., Penrice-Randal, R., Sharma, P., Kipar, A., Dong, X., Pennington, S., . . . Stewart, J. (2020). Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. doi:10.1101/2020.10.13.334532

DOI
10.1101/2020.10.13.334532
Journal article

Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV

Elkateb, H., Tatham, L. M., Cauldbeck, H., Niezabitowska, E., Owen, A., Rannard, S., & McDonald, T. (n.d.). Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV. International Journal of Pharmaceutics, 119794. doi:10.1016/j.ijpharm.2020.119794

DOI
10.1016/j.ijpharm.2020.119794
Journal article

Safety perspectives on presently considered drugs for the treatment of COVID‐19

Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (n.d.). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204

DOI
10.1111/bph.15204
Journal article

A living WHO guideline on drugs for covid-19

Agarwal, A., Hunt, B., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., . . . Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ (Clinical research ed.), 370, m3379. doi:10.1136/bmj.m3379

DOI
10.1136/bmj.m3379
Journal article

Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients

Dragovic, G., Dimitrijevic, B., Kusic, J., Soldatovic, I., Jevtovic, D., Olagunju, A., & Owen, A. (2020). Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(7), 1289-1295. doi:10.1111/bcp.14230

DOI
10.1111/bcp.14230
Journal article

Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz

Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.0000000000000401

DOI
10.1097/FPC.0000000000000401
Journal article

Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products

Halamoda-Kenzaoui, B., Box, H., van Elk, M., Gaitan, S., Geertsma, R. E., Gainza Lafuente, E., . . . Bremer-Hoffmann, S. (n.d.). Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products. Precision Nanomedicine, 3(2). doi:10.33218/001c.13521

DOI
10.33218/001c.13521
Journal article

Pharmacokinetics of HIV therapies in pregnant patients: an update

Neary, M., Owen, A., & Olagunju, A. (2020). Pharmacokinetics of HIV therapies in pregnant patients: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 16(6), 449-461. doi:10.1080/17425255.2020.1754792

DOI
10.1080/17425255.2020.1754792
Journal article

Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909

DOI
10.1002/cpt.1909
Journal article

Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population

Neary, M., Olagunju, A., Sarfo, F., Phillips, R., Moss, D., Owen, A., & Chadwick, D. (2020). Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1267-1271. doi:10.1093/jac/dkaa008

DOI
10.1093/jac/dkaa008
Journal article

Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection

Aljayyoussi, G., Rajoli, R. K. R., Pertinez, H., Pennington, S., Hong, D., O’Neill, P., . . . Biagini, G. (2020). Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection. doi:10.1101/2020.04.24.20078741

DOI
10.1101/2020.04.24.20078741
Journal article

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (n.d.). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of Virus Eradication, 6(2), 52-60.

Journal article

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379

DOI
10.1101/2020.04.16.20068379
Journal article

N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-lsoniazid Pharmacokinetics during Antituberculosis Treatment

Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-lsoniazid Pharmacokinetics during Antituberculosis Treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(4). doi:10.1128/AAC.02376-49

DOI
10.1128/AAC.02376-49
Journal article

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial

Dickinson, L., Gurjar, R., Stoehr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Boffito, M. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 628-639. doi:10.1093/jac/dkz479

DOI
10.1093/jac/dkz479
Journal article

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G&gt;T Genotypes

Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G&gt;T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19

DOI
10.1128/AAC.00947-19
Journal article

N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.

Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02376-19

DOI
10.1128/aac.02376-19
Journal article

HIV, ART and COVID-19: interplay and interactions

Sabin, C., Waters, L., Sparrowhawk, A., Owen, A., & Cevik, M. (2020). HIV, ART and COVID-19: interplay and interactions. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 23 (pp. 13). Retrieved from https://www.webofscience.com/

Conference Paper

2019

N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid /<i>N</i>-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment

DOI
10.1101/864454
Preprint

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies

Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068

DOI
10.1016/j.ejps.2019.105068
Journal article

Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations

Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529c

DOI
10.1039/c9na00529c
Journal article

On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019)

Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(9), 902. doi:10.1038/s41565-019-0538-3

DOI
10.1038/s41565-019-0538-3
Journal article

On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019)

Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(8), 811. doi:10.1038/s41565-019-0523-x

DOI
10.1038/s41565-019-0523-x
Journal article

On the issue of transparency and reproducibility in nanomedicine

Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine. NATURE NANOTECHNOLOGY, 14(7), 629-635. doi:10.1038/s41565-019-0496-9

DOI
10.1038/s41565-019-0496-9
Journal article

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Cerrone, M., Alfarisi, O., Neary, M., Marzinke, M. A., Parsons, T. L., Owen, A., . . . Boffito, M. (2019). Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1670-1678. doi:10.1093/jac/dkz068

DOI
10.1093/jac/dkz068
Journal article

Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726

DOI
10.1093/infdis/jiy726
Journal article

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

Francis, J., Zvada, S. P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., . . . McIlleron, H. M. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.01964-18

DOI
10.1128/AAC.01964-18
Journal article

Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies

Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Cerrone, M., Wang, X., Neary, M., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (2019). Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. CLINICAL INFECTIOUS DISEASES, 68(3), 446-452. doi:10.1093/cid/ciy491

DOI
10.1093/cid/ciy491
Journal article

Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery

Elbaz, N., Owen, A., Rannard, S., & McDonald, T. (2019). Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 258. Retrieved from https://www.webofscience.com/

Conference Paper

2018

Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro

Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482

DOI
10.1021/acs.molpharmaceut.8b00482
Journal article

Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee, S., Amanullah, F., Cattamanchi, A., Chaisson, R., Dobos, K. M., Fox, G. J., . . . Nahid, P. (2018). Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.. American journal of respiratory and critical care medicine. doi:10.1164/rccm.201806-1053pp

DOI
10.1164/rccm.201806-1053pp
Journal article

Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions

Hern, F. Y., Tatham, L., Owen, A., & Rannard, S. (2018). Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions. In 256th National Meeting and Exposition of the American-Chemical-Society (ACS) - Nanoscience, Nanotechnology and Beyond Vol. 256. Boston, MA.

Conference Paper

Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir

Savage, A., Ashcroft, S., Box, H., Sharp, J., Neary, M., Owen, A., & Rannard, S. (2018). Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika-Kibwika, P., . . . Boffito, M. (2018). Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. CLINICAL INFECTIOUS DISEASES, 67(5), 785-790. doi:10.1093/cid/ciy161

DOI
10.1093/cid/ciy161
Journal article

The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV

Hobson, J. J., Owen, A., & Rannard, S. P. (2018). The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV. NANOMEDICINE, 13(16), 1963-1965. doi:10.2217/nnm-2018-0182

DOI
10.2217/nnm-2018-0182
Journal article

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18

DOI
10.1128/AAC.00717-18
Journal article

The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation

Siccardi, M., Rannard, S., & Owen, A. (2018). The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 131, 116-121. doi:10.1016/j.addr.2018.06.016

DOI
10.1016/j.addr.2018.06.016
Journal article

Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens

Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART

Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515

DOI
10.1093/jac/dkx515
Journal article

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease

Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17

DOI
10.1128/aac.01909-17
Journal article

Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.

Cerrone, M., Xinhu, W., Neary, M. G., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (n.d.). Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.. In CROI. Boston, MA, USA.

Conference Paper

Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.

Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.

Conference Paper

Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.

Cerrone, M., Alfarisi, O., Neary, M. G., Marzinke, O., Parsons, T., Owen, A., . . . Boffito, M. (n.d.). Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.. In CROI. Boston, MA, USA.

Conference Paper

Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs

Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507

DOI
10.1093/jac/dkx507
Journal article

Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens

Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/

Conference Paper

LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS

Bakshi, R., Tatham, L., Savage, A., Tripathi, A., Mlambo, G., Ippolito, M., . . . Shapiro, T. (2018). LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 99 (pp. 94). Retrieved from https://www.webofscience.com/

Conference Paper

Potential for immune modulation by inhibition of autophagic processes.

David, C., Owen, A., & Liptrott, N. J. (2018). Potential for immune modulation by inhibition of autophagic processes.. Poster session presented at the meeting of Nanomedicine's Early Career Researchers Meeting. London.

Poster

Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling

Saeheng, T., Na-Bangchang, K., Rajoli, R. K. R., Siccardi, M., Owen, A., & Laothavorn, J. (2018). Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018(0). doi:10.1254/jpssuppl.wcp2018.0_po1-11-30

DOI
10.1254/jpssuppl.wcp2018.0_po1-11-30
Journal article

Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage

Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/

Conference Paper

2017

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update

Neary, M., & Owen, A. (2017). Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(11), 1169-1181. doi:10.1080/17425255.2017.1391214

DOI
10.1080/17425255.2017.1391214
Journal article

The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine

Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667

DOI
10.1002/cpt.667
Journal article

Foreword

Owen, A. (2017). Foreword. Journal of Interdisciplinary Nanomedicine, 2(1), 4. doi:10.1002/jin2.23

DOI
10.1002/jin2.23
Journal article

Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs

Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485

DOI
10.1093/jac/dkw485
Journal article

ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.

Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.

Conference Paper

Current Progress in the Pharmacogenetics of Infectious Disease Therapy

Elliot, E., Mahungu, T., & Owen, A. (2017). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES, 2ND EDITION (pp. 435-457). doi:10.1016/B978-0-12-799942-5.00019-6

DOI
10.1016/B978-0-12-799942-5.00019-6
Chapter

19 Current Progress in the Pharmacogenetics of Infectious Disease Therapy

Elliot, E., Mahungu, T., & Owen, A. (2017). 19 Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In Genetics and Evolution of Infectious Diseases (pp. 435-457). Elsevier. doi:10.1016/b978-0-12-799942-5.00019-6

DOI
10.1016/b978-0-12-799942-5.00019-6
Chapter

A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo

Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001

DOI
10.1515/ejnm-2017-0001
Journal article

Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.

David, C., Giardiello, M., Rannard, S. P., Owen, A., & Liptrott, N. J. (2017). Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.. Poster session presented at the meeting of BSNM Early Career Researchers' Meeting. Belfast.

Poster

Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients

Sandkovsky, U., Podany, A. T., Fletcher, C. V., Owen, A., Felton-Coleman, A., Winchester, L. C., . . . Swindells, S. (2017). Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(1), 200-204. doi:10.1093/jac/dkw403

DOI
10.1093/jac/dkw403
Journal article

Integrated pharmacokinetic modelling for accelerated nanomedicine translation

Siccardi, M., Löffler, B., Balogh, L., & Owen, A. (2017). Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 9(1), 1-3. doi:10.1515/ejnm-2016-0041

DOI
10.1515/ejnm-2016-0041
Journal article

Long acting injectable formulations of atovaquone for malaria prophylaxis

Savage, A., Tatham, L., Bakshi, R., Tripathi, A., Mlambo, G., Shapiro, T., . . . Rannard, S. (2017). Long acting injectable formulations of atovaquone for malaria prophylaxis. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules

Hobson, J., Edwards, S., Owen, A., & Rannard, S. (2017). New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum

Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika, P., . . . Boffito, M. (2017). Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 122). Retrieved from https://www.webofscience.com/

Conference Paper

Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines

Giardiello, M., McDonald, T., Liptrott, N., Martin, P., Smith, D., Siccardi, M., . . . Rannard, S. (2017). Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot

Hobson, J., Curley, P., Al-khouja, A., Meyers, C., Flexner, C., Owen, A., & Rannard, S. (2017). Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/

Conference Paper

USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES

Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.099

DOI
10.1016/j.dmpk.2016.10.099
Conference Paper

2016

Computational Predictive Models for Nanomedicine

Siccardi, M., Schipani, A., & Owen, A. (n.d.). Computational Predictive Models for Nanomedicine. In Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production (pp. 379-402). Wiley-VCH Verlag GmbH & Co. KGaA.

Chapter

Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma

McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2016). Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma. HIV CLINICAL TRIALS, 17(5), 197-203. doi:10.1080/15284336.2016.1210719

DOI
10.1080/15284336.2016.1210719
Journal article

Abstract

Abstract (2016). In Journal of Interdisciplinary Nanomedicine Vol. 1 (pp. 35-82). Wiley. doi:10.1002/jin2.14

DOI
10.1002/jin2.14
Conference Paper

Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles

Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. In British Society of Nanomedicine Early Career Meeting Vol. 1 (pp. 78). Swansea University. doi:10.1002/jin2.14

DOI
10.1002/jin2.14
Conference Paper

Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study

Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227

DOI
10.1097/FPC.0000000000000227
Journal article

Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers

Tatham, L., Ford, J., Rogers, H., Rannard, S., & Owen, A. (2016). Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers. In Controlled Release Society Annual Meeting & Exposition. Seattle, Washington.

Conference Paper

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5

DOI
10.1007/s40262-015-0360-5
Journal article

Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles

Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. P. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. Poster session presented at the meeting of Royal Society of Chemistry Early Career Symposium. University of Strathclyde.

Poster

Foreword

Owen, A. (2016). Foreword. Journal of Interdisciplinary Nanomedicine, 1(2), 34. doi:10.1002/jin2.15

DOI
10.1002/jin2.15
Journal article

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis

Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016

DOI
10.2217/pgs-2015-0016
Journal article

Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review

Owen, A., Rannard, S. P., Bawa, R., & Feng, S. -S. (2016). Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 1223-1237). Retrieved from https://www.webofscience.com/

Chapter

Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields

Giardiello, M., Hatton, F. L., Slater, R. A., Chambon, P., North, J., Peacock, A. K., . . . Rannard, S. P. (2016). Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. Nanoscale, 8(13), 7224-7231. doi:10.1039/c6nr00788k

DOI
10.1039/c6nr00788k
Journal article

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425

DOI
10.1093/jac/dkv425
Journal article

Handbook of Immunological Properties of Engineered Nanomaterials

Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677

DOI
10.1142/9677
Chapter

Interdisciplinary nanomedicine publications through interdisciplinary peer-review

Owen, A., Rannard, S., Bawa, R., & Feng, S. -S. (2016). Interdisciplinary nanomedicine publications through interdisciplinary peer-review. Journal of Interdisciplinary Nanomedicine, 1(1), 4-8. doi:10.1002/jin2.1

DOI
10.1002/jin2.1
Journal article

Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles

Silva, A. H., Locatelli, C., Filippin-Monteiro, F. B., Martin, P., Liptrott, N. J., Zanetti-Ramos, B. G., . . . Creczynski-Pasa, T. B. (2016). Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. TOXICOLOGY LETTERS, 246, 17-27. doi:10.1016/j.toxlet.2016.01.018

DOI
10.1016/j.toxlet.2016.01.018
Journal article

Emerging nanomedicine applications and manufacturing: progress and challenges

Sartain, F., Greco, F., Hill, K., Rannard, S., & Owen, A. (2016). Emerging nanomedicine applications and manufacturing: progress and challenges. NANOMEDICINE, 11(6), 577-580. doi:10.2217/nnm.16.17

DOI
10.2217/nnm.16.17
Journal article

Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery

Liptrott, N. J., Curley, P., Tatham, L. M., & Owen, A. (2016). Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. In Frontiers in Nanobiomedical Research (pp. 205-239). WORLD SCIENTIFIC. doi:10.1142/9789813140479_0009

DOI
10.1142/9789813140479_0009
Chapter

Solid drug nanoparticles: Methods for production and pharmacokinetic benefits

Owen, A., & Rannard, S. P. (2016). Solid drug nanoparticles: Methods for production and pharmacokinetic benefits. In Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications (Vol. 1, pp. 211-232). doi:10.4032/9789814669214

DOI
10.4032/9789814669214
Chapter

Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.

Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.

Conference Paper

Association of SLCO1B1 521T &gt; C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study

Gurjar, R., Boffito, M., D'Avolio, A., Schwimmer, C., Yazdanpanah, Y., Doroana, M., . . . Owen, A. (2016). Association of SLCO1B1 521T &gt; C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/

Conference Paper

Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.

David, C., Owen, A., & Liptrott, N. J. (2016). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of University of Liverpool ITM Research Day. Liverpool.

Poster

Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis

Hennig, S., Naiker, S., Reddy, T., Egan, D., Kellerman, T., Wiesner, L., . . . Pym, A. (2016). Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 617-620. doi:10.1128/AAC.01195-15

DOI
10.1128/AAC.01195-15
Journal article

Intracellular Transport and Unpacking of Polyplex Nanoparticles

Rosenkranz, A. A., Khramtsov, Y. V., Ulasov, A. V., Rodichenko, N., & Sobolev, A. S. (2016). Intracellular Transport and Unpacking of Polyplex Nanoparticles. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 823-843). Retrieved from https://www.webofscience.com/

Chapter

The Challenge of Regulating Nanomedicine: Key Issues

Bawa, R., Barenholz, Y., & Owen, A. (2016). The Challenge of Regulating Nanomedicine: Key Issues. In NANOMEDICINES: DESIGN, DELIVERY AND DETECTION (Vol. 51, pp. 290-314). Retrieved from https://www.webofscience.com/

Chapter

Towards a computational prediction of nanoparticle pharmacokinetics and distribution

Siccardi, M., & Owen, A. (n.d.). Towards a computational prediction of nanoparticle pharmacokinetics and distribution. Journal of In Silico &amp; In Vitro Pharmacology, 02(01). doi:10.21767/2469-6692.10008

DOI
10.21767/2469-6692.10008
Journal article

2015

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV

Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1

DOI
10.1007/s40262-014-0227-1
Journal article

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

Nelson, A. G., Zhang, X., Ganapathi, U., Szekely, Z., Flexner, C. W., Owen, A., & Sinko, P. J. (2015). Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. JOURNAL OF CONTROLLED RELEASE, 219, 669-680. doi:10.1016/j.jconrel.2015.08.042

DOI
10.1016/j.jconrel.2015.08.042
Journal article

Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation

Naisbitt, D., Yang, E. L., Alhaidari, M., Berry, N., Lawrenson, A. S., Farrell, J., . . . Park, B. (2015). Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS, 29(18), 2385-2395. doi:10.1097/QAD.0000000000000867

DOI
10.1097/QAD.0000000000000867
Journal article

Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models

Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/

Conference Paper

Class-specific relative genetic contribution for key antiretroviral drugs

Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207

DOI
10.1093/jac/dkv207
Journal article

Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles

Martin, P., Giardiello, M., McDonald, T. C., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015). Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. MOLECULAR PHARMACEUTICS, 12(10), 3556-3568. doi:10.1021/acs.molpharmaceut.5b00204

DOI
10.1021/acs.molpharmaceut.5b00204
Journal article

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

Owen, A., & Rannard, S. (2015). Considerations for clinically-relevant nanomedicine therapies for chronic diseases. NANOMEDICINE, 10(20), 3103-3107. doi:10.2217/nnm.15.135

DOI
10.2217/nnm.15.135
Journal article

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots

Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174

DOI
10.1093/jac/dkv174
Journal article

Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons

Rogers, H. E., Chambon, P., Auty, S. E. R., Hern, F. Y., Owen, A., & Rannard, S. P. (2015). Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. SOFT MATTER, 11(35), 7005-7015. doi:10.1039/c5sm00673b

DOI
10.1039/c5sm00673b
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156

DOI
10.1002/cpt.156
Journal article

Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs

Savage, A. C., Tatham, L. M., Owen, A., & Rannard, S. P. (2015). Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs. Poster session presented at the meeting of British Society of Nanomedicine Young Researchers Meeting. University of Liverpool.

Poster

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317

DOI
10.1093/cid/civ317
Journal article

Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

McIlleron, H., Abdel-Rahman, S., Dave, J. A., Blockman, M., & Owen, A. (2015). Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. JOURNAL OF INFECTIOUS DISEASES, 211, S115-S125. doi:10.1093/infdis/jiu600

DOI
10.1093/infdis/jiu600
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.

Journal article

The Application of Nanotechnology to Drug Delivery in Medicine

McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5

DOI
10.1016/b978-0-444-62747-6.00007-5
Chapter

Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry

Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53

DOI
10.2217/pgs.15.53
Journal article

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77

DOI
10.2217/NNM.14.77
Journal article

Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics

Tatham, L. M., Rannard, S. P., & Owen, A. (2015). Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. THERAPEUTIC DELIVERY, 6(4), 469-490. doi:10.4155/TDE.15.4

DOI
10.4155/TDE.15.4
Journal article

No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults

Sirirungsi, W., Urien, S., Harrison, L., Kamkon, J., Tawon, Y., Luekamlung, N., . . . Cressey, T. R. (2015). No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 68(4), E56-E59. doi:10.1097/QAI.0000000000000504

DOI
10.1097/QAI.0000000000000504
Journal article

Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media

Ford, J., Chambon, P., North, J., Hatton, F. L., Giardiello, M., Owen, A., & Rannard, S. P. (2015). Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. MACROMOLECULES, 48(6), 1883-1893. doi:10.1021/acs.macromol.5b00099

DOI
10.1021/acs.macromol.5b00099
Journal article

Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics

Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43

DOI
10.1002/cpt.43
Journal article

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS

Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420

DOI
10.1093/jac/dku420
Journal article

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.

Journal article

Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine

McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5

DOI
10.1016/b978-0-444-62747-6.00007-5
Chapter

Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.

David, C., Owen, A., & Liptrott, N. J. (2015). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of European Nanomedicine Meeting. Grenoble.

Poster

Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium

Hatton, F. L., Tatham, L. M., Tidbury, L. R., Chambon, P., He, T., Owen, A., & Rannard, S. P. (2015). Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. CHEMICAL SCIENCE, 6(1), 326-334. doi:10.1039/c4sc02889a

DOI
10.1039/c4sc02889a
Journal article

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078

DOI
10.3389/fphar.2015.00078
Journal article

Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.

David, C., Liptrott, N. J., & Owen, A. (2015). Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.. Poster session presented at the meeting of University of Liverpool Poster Day. Liverpool.

Poster

Optimisation of methodology to assess the impact of nanomaterials on autophagy.

David, C., Owen, A., & Liptrott, N. J. (2015). Optimisation of methodology to assess the impact of nanomaterials on autophagy.. Poster session presented at the meeting of BSNM Young Researcher Meeting. Liverpool.

Poster

Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine

Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8

DOI
10.1007/s40262-014-0184-8
Journal article

Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.

David, C., Raymant, M. L., Owen, A., & Liptrott, N. J. (2015). Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.. Poster session presented at the meeting of Nanotechnology in Medicine. Manchester.

Poster

pH-Responsive hyperbranched-polydendrons for drug delivery applications

Rogers, H., Tatham, L., Chambon, P., Owen, A., & Rannard, S. (2015). pH-Responsive hyperbranched-polydendrons for drug delivery applications. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 250. Retrieved from https://www.webofscience.com/

Conference Paper

2014

<i>CYP2B6</i> 516G&gt;T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients

Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G&gt;T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098

DOI
10.1097/FTD.0000000000000098
Journal article

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication

Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312

DOI
10.1093/jac/dku312
Journal article

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication

Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312

DOI
10.1093/jac/dku312
Journal article

Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'

Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'. Nanomedicine, 9(16), 2467-2479. doi:10.2217/nnm.14.38

DOI
10.2217/nnm.14.38
Journal article

Chemical modification of the 6'‐amino cyclopropyl of abacavir eliminates HLA‐B*57:01‐restricted CD8+ T‐cell activation without loss of antiviral activity

Alhaidari, M., Yang, E., Berry, N., Owen, A., Clarke, S., O'Neill, P., . . . Park, K. (2014). Chemical modification of the 6'‐amino cyclopropyl of abacavir eliminates HLA‐B*57:01‐restricted CD8+ T‐cell activation without loss of antiviral activity. Clinical and Translational Allergy, 4(S3). doi:10.1186/2045-7022-4-s3-p40

DOI
10.1186/2045-7022-4-s3-p40
Journal article

The application of nanotechnology in medicine: treatment and diagnostics

Owen, A., Dufes, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). The application of nanotechnology in medicine: treatment and diagnostics. NANOMEDICINE, 9(9), 1291-1294. doi:10.2217/NNM.14.93

DOI
10.2217/NNM.14.93
Journal article

Enabling the genomic revolution in Africa

Rotimi, C. (2014). Enabling the genomic revolution in Africa. SCIENCE, 344(6190), 1346-1348. doi:10.1126/science.1251546

DOI
10.1126/science.1251546
Journal article

Polydendrons

Rannard, S., Owen, A., Rogers, H., Hatton, F., & Southworth, F. (2014, June 13). WO2014199175 A1, Polydendrons.

Patent

Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol

Dwyer, A. B., Chambon, P., Town, A., He, T., Owen, A., & Rannard, S. P. (2014). Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol. POLYMER CHEMISTRY, 5(11), 3608-3616. doi:10.1039/c4py00182f

DOI
10.1039/c4py00182f
Journal article

Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents

Hatton, F. L., Chambon, P., McDonald, T. O., Owen, A., & Rannard, S. P. (2014). Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. CHEMICAL SCIENCE, 5(5), 1844-1853. doi:10.1039/c4sc00360h

DOI
10.1039/c4sc00360h
Journal article

Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation

McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280

DOI
10.1002/adhm.201300280
Journal article

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients

Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372

DOI
10.1093/jac/dkt372
Journal article

The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study

Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2014). The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study. LANCET, 383, 44. Retrieved from https://www.webofscience.com/

Journal article

<i>CYP3A4</i>*22 (c.522-191 C&gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults

Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C&gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073

DOI
10.1097/FPC.0000000000000073
Journal article

<i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles

King, S. C., Oliveira, M., Moisi, D., Brenner, B., Giardiello, M., Rannard, S. P., . . . Geretti, A. M. (2014). <i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles. In ANTIVIRAL THERAPY Vol. 19 (pp. A126). Retrieved from https://www.webofscience.com/

Conference Paper

CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.

Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.. Ther Drug Monit..

Journal article

Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014

Owen, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014. Nanomedicine.

Journal article

Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy

McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2014). Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy. HIV MEDICINE, 15, 53-54. Retrieved from https://www.webofscience.com/

Journal article

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).

Journal article

Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine

Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.

Poster

Investigating the interaction of gold nanoparticles with the human immune system

Kendall, E., Liptrott, N., & Owen, A. (2014). Investigating the interaction of gold nanoparticles with the human immune system. SCOTTISH MEDICAL JOURNAL, 59(1), E34. Retrieved from https://www.webofscience.com/

Journal article

Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration

Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.

Poster

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents

Boffito, M., Jackson, A., Owen, A., & Becker, S. (2014). New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. DRUGS, 74(1), 7-13. doi:10.1007/s40265-013-0163-7

DOI
10.1007/s40265-013-0163-7
Journal article

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'

Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (London).

Journal article

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.

Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.. J Antimicrob Chemother., 69(2), 491-499.

Journal article

Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir

Alvarez, E., Owen, A., Martin Carbonero, L., Siccardi, M., Valencia, E., Moreno, V., . . . Rodriguez-Novoa, S. (2014). Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir. In ANTIVIRAL THERAPY Vol. 19 (pp. A11). Retrieved from https://www.webofscience.com/

Conference Paper

Special issue of BJP on Nanomedicine

Owen, A. (2014). Special issue of BJP on Nanomedicine. BRITISH JOURNAL OF PHARMACOLOGY, 171(17), 3961-3962. doi:10.1111/bph.12820

DOI
10.1111/bph.12820
Journal article

Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs

Owen, A., & Curley, P. (2014). Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. In Humanized Mice for HIV Research (pp. 339-360). Springer New York. doi:10.1007/978-1-4939-1655-9_28

DOI
10.1007/978-1-4939-1655-9_28
Chapter

The application of nanotechnology to drug delivery in Medicine

McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Owen, A., & Rannard, S. (2014). The application of nanotechnology to drug delivery in Medicine. In P. Dolez (Ed.), Nano Engineering: Global Approaches to Health and Safety Issues (pp. 1-500). Toronto: Elsevier Health Sciences.

Chapter

The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents

Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.

Poster

The role of drug transporters in the kidney: lessons from tenofovir

Moss, D. M., Neary, M., & Owen, A. (2014). The role of drug transporters in the kidney: lessons from tenofovir. FRONTIERS IN PHARMACOLOGY, 5. doi:10.3389/fphar.2014.00248

DOI
10.3389/fphar.2014.00248
Journal article

2013

Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013). Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 6366-6369. doi:10.1128/AAC.01124-13

DOI
10.1128/AAC.01124-13
Journal article

Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation

Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225

DOI
10.1093/jac/dkt225
Journal article

Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>

Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13

DOI
10.1128/AAC.01421-13
Journal article

Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA

Williamson, B., Soars, A. C., Owen, A., White, P., Riley, R. J., & Soars, M. G. (2013). Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. XENOBIOTICA, 43(10), 920-931. doi:10.3109/00498254.2013.776194

DOI
10.3109/00498254.2013.776194
Journal article

High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>

McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>. JOURNAL OF MATERIALS CHEMISTRY B, 1(35), 4455-4465. doi:10.1039/c3tb20543f

DOI
10.1039/c3tb20543f
Journal article

Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67

DOI
10.2217/fvl.13.67
Journal article

Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy

Geretti, A. M., Fox, Z., Johnson, J. A., Booth, C., Lipscomb, J., Stuyver, L. J., . . . Phillips, A. (2013). Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLOS ONE, 8(7). doi:10.1371/journal.pone.0069266

DOI
10.1371/journal.pone.0069266
Journal article

Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 52(7), 613-614. doi:10.1007/s40262-013-0066-5

DOI
10.1007/s40262-013-0066-5
Journal article

Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients

Martin, P., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2013). Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients. MOLECULAR PHARMACEUTICS, 10(7), 2739-2748. doi:10.1021/mp400175n

DOI
10.1021/mp400175n
Journal article

Predicting intestinal absorption of raltegravir using a population-based ADME simulation

Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084

DOI
10.1093/jac/dkt084
Journal article

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7

DOI
10.1007/s40262-013-0056-7
Journal article

Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients

Molto, J., Xinarianos, G., Miranda, C., Pushpakom, S., Cedeno, S., Clotet, B., . . . Valle, M. (2013). Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. CLINICAL PHARMACOKINETICS, 52(7), 543-553. doi:10.1007/s40262-013-0057-6

DOI
10.1007/s40262-013-0057-6
Journal article

ABCB1 single nucleotide polymorphisms (1236C &gt; T, 2677G &gt; T, and 3435C &gt; T) do not affect transport activity of human P-glycoprotein

Dickens, D., Owen, A., Alfirevic, A., & Pirmohamed, M. (2013). ABCB1 single nucleotide polymorphisms (1236C &gt; T, 2677G &gt; T, and 3435C &gt; T) do not affect transport activity of human P-glycoprotein. PHARMACOGENETICS AND GENOMICS, 23(6), 314-323. doi:10.1097/FPC.0b013e328360d10c

DOI
10.1097/FPC.0b013e328360d10c
Journal article

Transport of gabapentin by LAT1 (SLC7A5)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Rädisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI
10.1016/j.bcp.2013.03.022
Journal article

Transport of gabapentin by LAT1 (SLC7A5)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Raedisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). BIOCHEMICAL PHARMACOLOGY, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI
10.1016/j.bcp.2013.03.022
Journal article

A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp

Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. PLOS ONE, 8(5). doi:10.1371/journal.pone.0064854

DOI
10.1371/journal.pone.0064854
Journal article

Compositions of Lopinavir and Ritonavir

Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2013). Compositions of Lopinavir and Ritonavir.

Patent

HIV Drug Nanodispersions

Rannard, S., Owen, A., Giardiello, M., McDonald, T., Smith, D., & Martin, P. (2013). HIV Drug Nanodispersions.

Patent

Nanoparticles Formulation of Lopinavir

Rannard, S., Owen, A., Smith, S., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2013). Nanoparticles Formulation of Lopinavir.

Patent

Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor

Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., & la Porte, C. J. L. (2013). Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. THERAPEUTIC DRUG MONITORING, 35(1), 78-83. doi:10.1097/FTD.0b013e318274197e

DOI
10.1097/FTD.0b013e318274197e
Journal article

'Research Spotlight: Nanomedicines for HIV therapy'

Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). 'Research Spotlight: Nanomedicines for HIV therapy'. Therapeutic Delivery, 4(2), 153.

Journal article

A multi-system approach assessing the interaction of anticonvulsants with P-gp.

Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A multi-system approach assessing the interaction of anticonvulsants with P-gp.. PloS One, 8(5), e64854.

Journal article

Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles

Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.

Conference Paper

HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml

Geretti, A. M., Cozzi-Lepri, A., Vitiello, P., King, S., Owen, A., & Phillips, A. (2013). HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml. In ANTIVIRAL THERAPY Vol. 18 (pp. A27). Retrieved from https://www.webofscience.com/

Conference Paper

High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli

McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. Journal of Materials Chemistry B, 1(35), 4455. doi:10.1039/c3tb20543f

DOI
10.1039/c3tb20543f
Journal article

Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach

Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.

Poster

Nanomedicines for HIV therapy.

Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156

DOI
10.4155/tde.12.156
Journal article

Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach

Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.

Conference Paper

Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching

Giardiello, M., McDonald, T. O., Lee, J. -S., Roberts, A. D., Owen, A., & Rannard, S. P. (2013). Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. GREEN CHEMISTRY, 15(6), 1590-1599. doi:10.1039/c3gc40573g

DOI
10.1039/c3gc40573g
Journal article

Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies

Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

DOI
10.1097/QAI.0b013e3182737231
Journal article

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

DOI
10.1097/QAI.0b013e3182737231
Journal article

Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system

Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.

Poster

2012

Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles

Giardiello, M., McDonald, T. O., Martin, P., Owen, A., & Rannard, S. P. (2012). Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles. JOURNAL OF MATERIALS CHEMISTRY, 22(47), 24744-24752. doi:10.1039/c2jm34974d

DOI
10.1039/c2jm34974d
Journal article

Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor

Maguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T., Doherty, D., . . . Thompson, P. (2012). Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 364(1-2), 54-64. doi:10.1016/j.mce.2012.08.007

DOI
10.1016/j.mce.2012.08.007
Journal article

Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model

Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339

DOI
10.7448/IAS.15.6.18339
Journal article

Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model

Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61

DOI
10.1038/clpt.2012.61
Journal article

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding

Olagunju, A., Owen, A., & Creesey, T. R. (2012). Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. PHARMACOGENOMICS, 13(13), 1501-1522. doi:10.2217/PGS.12.138

DOI
10.2217/PGS.12.138
Journal article

Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095

DOI
10.3851/IMP2095
Journal article

Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems

McDonald, T. O., Martin, P., Patterson, J. P., Smith, D., Giardiello, M., Marcello, M., . . . Rannard, S. (2012). Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. ADVANCED FUNCTIONAL MATERIALS, 22(12), 2469-2478. doi:10.1002/adfm.201103059

DOI
10.1002/adfm.201103059
Journal article

Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>

Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11

DOI
10.1128/AAC.06407-11
Journal article

\Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals

Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Owen, A., . . . Csajka, C. (2012). \Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 2959-2966. doi:10.1128/AAC.05424-11

DOI
10.1128/AAC.05424-11
Journal article

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50a

DOI
10.1097/FTD.0b013e31824aa50a
Journal article

Lamotrigine is a substrate for OCT1 in brain endothelial cells

Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032

DOI
10.1016/j.bcp.2011.12.032
Journal article

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies

Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491

DOI
10.1093/jac/dkr491
Journal article

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies

Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 675-680. doi:10.1093/jac/dkr491

DOI
10.1093/jac/dkr491
Journal article

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg

Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 671-674. doi:10.1093/jac/dkr493

DOI
10.1093/jac/dkr493
Journal article

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2012). Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 54(5), 724-732. doi:10.1093/cid/cir936

DOI
10.1093/cid/cir936
Journal article

Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e

DOI
10.1097/FPC.0b013e32834dd82e
Journal article

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e

DOI
10.1097/fpc.0b013e32834dd82e
Journal article

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.

Journal article

Investigation of the potential interactions of efavirenz with the GABAa receptor

Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.

Poster

Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.

Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.. Journal of Antimicrobial Chemotherapy, 67, 671-674.

Journal article

PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL

Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Edwards, D., . . . Back, D. (2012). PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL. CLINICAL PHARMACOLOGY & THERAPEUTICS, 91, S104. Retrieved from https://www.webofscience.com/

Journal article

Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals

Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Boffito, M., . . . Csajka, C. (2012). Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 56, 2959-2966.

Journal article

Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation

Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 244. Retrieved from https://www.webofscience.com/

Journal article

Rapid "bottom-​up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation

Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-​up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. In 244th ACS National Meeting & Exposition (pp. COLL-196). Philadelphia: ACS.

Conference Paper

2011

IFN-γ 874A&gt;T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients

Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A&gt;T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441c

DOI
10.1097/QAI.0b013e318236441c
Journal article

Current Progress in the Pharmacogenetics of Infectious Disease Therapy

Mahungu, T., & Owen, A. (2011). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES (pp. 555-578). doi:10.1016/B978-0-12-384890-1.00020-0

DOI
10.1016/B978-0-12-384890-1.00020-0
Chapter

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy

Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10(1). doi:10.1186/1476-4598-10-37

DOI
10.1186/1476-4598-10-37
Journal article

Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272

DOI
10.1093/jac/dkr272
Journal article

The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4122-4127. doi:10.1128/AAC.01833-10

DOI
10.1128/AAC.01833-10
Journal article

Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215

DOI
10.1093/infdis/jir215
Journal article

Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215

DOI
10.1093/infdis/jir215
Journal article

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087

DOI
10.1093/jac/dkr087
Journal article

The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein

Vogler, M., Dickens, D., Dyer, M. J. S., Owen, A., Pirmohamed, M., & Cohen, G. M. (2011). The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 408(2), 344-349. doi:10.1016/j.bbrc.2011.04.043

DOI
10.1016/j.bbrc.2011.04.043
Journal article

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy

Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. MOLECULAR CANCER, 10. doi:10.1186/1476-4598-10-37

DOI
10.1186/1476-4598-10-37
Journal article

Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008)

Garcia-Diaz, A., Lok, C. B., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2011). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(3), 688. doi:10.1093/jac/dkq534

DOI
10.1093/jac/dkq534
Journal article

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 7(3), 341-352. doi:10.1517/17425255.2011.553600

DOI
10.1517/17425255.2011.553600
Journal article

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort

Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800

DOI
10.1371/journal.pone.0016800
Journal article

Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i>

Chaijaroenkul, W., Ward, S. A., Mungthin, M., Johnson, D., Owen, A., Bray, P. G., & Na-Bangchang, K. (2011). Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i>. MALARIA JOURNAL, 10. doi:10.1186/1475-2875-10-42

DOI
10.1186/1475-2875-10-42
Journal article

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10

DOI
10.1128/AAC.00623-10
Journal article

20 Current Progress in the Pharmacogenetics of Infectious Disease Therapy

Mahungu, T., & Owen, A. (2011). 20 Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In Genetics and Evolution of Infectious Disease (pp. 555-578). Elsevier. doi:10.1016/b978-0-12-384890-1.00020-0

DOI
10.1016/b978-0-12-384890-1.00020-0
Chapter

Adipogenic gene variants in patients with HIV-associated lipodystrophy

Pushpakom, S. P., Owen, A., Vilar, F. J., Castro, H., Dunn, D. T., Back, D. J., & Pirmohamed, M. (2011). Adipogenic gene variants in patients with HIV-associated lipodystrophy. PHARMACOGENETICS AND GENOMICS, 21(2), 76-83. doi:10.1097/FPC.0b013e328342a917

DOI
10.1097/FPC.0b013e328342a917
Journal article

Compositions of Lopinavir & Ritonavir

Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2011). Compositions of Lopinavir & Ritonavir.

Patent

HIV Drug Nanodispersions

Rannard, S., Owen, A., McDonald, T., Smith, D., Giardiello, M., & Martin, P. (2011). HIV Drug Nanodispersions.

Patent

Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies

McDonald, T. O., Giardielo, M., Smith, D., Martin, P., Owen, A., & Rannard, S. P. (2011). Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies. In 2nd Nano Today Conference (pp. 1). Waikoloa: Nano Today.

Conference Paper

Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems

McDonald, T., Martin, P., Giardiello, M., Smith, D., Owen, A., & Rannard, S. (2011). Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems. In Nano Today (pp. 1). Waikoloa: Nano Today.

Conference Paper

Nanoparticles Formulation of Lopinavir

Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2011). Nanoparticles Formulation of Lopinavir.

Patent

Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy

Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10, 37.

Journal article

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications

Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother, 55(9), 4122-4127.

Journal article

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. Expert Opinion on Drug Metabolism and Toxicology.

Journal article

2010

Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&gt;C polymorphism

Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&gt;C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efb

DOI
10.1097/FPC.0b013e3283402efb
Journal article

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10

DOI
10.1128/AAC.00781-10
Journal article

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10

DOI
10.1128/aac.00781-10
Journal article

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV‐infected patients

Zhang, Y., Owen, A., Egan, D., & Sarfo, S. F. (2010). Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV‐infected patients. Journal of the International AIDS Society, 13(S4). doi:10.1186/1758-2652-13-s4-p183

DOI
10.1186/1758-2652-13-s4-p183
Journal article

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., Back, D. J., . . . Owen, A. (2010). SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients. Journal of the International AIDS Society, 13, P178. doi:10.1186/1758-2652-13-s4-p178

DOI
10.1186/1758-2652-13-s4-p178
Journal article

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

Carr, D. F., la Porte, C. J. L., Pirmohamed, M., Owen, A., & Cortes, C. P. (2010). Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(9), 1889-1893. doi:10.1093/jac/dkq260

DOI
10.1093/jac/dkq260
Journal article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms

Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02d

DOI
10.1097/FPC.0b013e328335b02d
Journal article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d

DOI
10.1097/fpc.0b013e328335b02d
Journal article

Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells

Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. ACTA PHARMACOLOGICA SINICA, 31(1), 51-65. doi:10.1038/aps.2009.187

DOI
10.1038/aps.2009.187
Journal article

Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens

Pushpakom, S., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2

Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir

Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.

Journal article

The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes

Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. BRITISH JOURNAL OF PHARMACOLOGY, 159(2), 484-493. doi:10.1111/j.1476-5381.2009.00552.x

DOI
10.1111/j.1476-5381.2009.00552.x
Journal article

2009

Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.

Journal article

Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335

DOI
10.1093/jac/dkp335
Journal article

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.

Journal article

Nanomedicine: Not a case of "One size fits all"

Rannard, S., & Owen, A. (2009). Nanomedicine: Not a case of "One size fits all". NANO TODAY, 4(5), 382-384. doi:10.1016/j.nantod.2009.07.002

DOI
10.1016/j.nantod.2009.07.002
Journal article

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.x

DOI
10.1111/j.1365-2125.2009.03462.x
Journal article

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.

Journal article

The Relationships of ABCB1 3435C&gt;T and CYP2B6 516G&gt;T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C&gt;T and CYP2B6 516G&gt;T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78

DOI
10.1038/clpt.2009.78
Journal article

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507

DOI
10.1086/598507
Journal article

Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives

Vandekerckhove, L. P. R., Christ, F., Debyser, Z., Owen, A., Back, D., Voet, A., . . . Vogelaers, D. (2009). Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. In ANTIVIRAL RESEARCH: STRATEGIES IN ANTIVIRAL DRUG DISCOVERY (pp. 71-+). Retrieved from https://www.webofscience.com/

Chapter

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.x

DOI
10.1111/j.1468-1293.2008.00689.x
Journal article

<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa

Alker, A. P., Juliano, J. J., & Meshnick, S. R. (2009). <i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(4), 1722. doi:10.1128/AAC.01427-08

DOI
10.1128/AAC.01427-08
Journal article

The impact of pharmacogenetics on HIV therapy

Mahungu, T. W., Johnson, M. A., Owen, A., & Back, D. J. (2009). The impact of pharmacogenetics on HIV therapy. INTERNATIONAL JOURNAL OF STD & AIDS, 20(3), 145-151. doi:10.1258/ijsa.2008.008369

DOI
10.1258/ijsa.2008.008369
Journal article

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x

DOI
10.1111/j.1476-5381.2008.00050.x
Journal article

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x

DOI
10.1111/j.1476-5381.2008.00050.x
Journal article

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.

Journal article

2008

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry

Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010

DOI
10.1016/j.jim.2008.09.010
Journal article

Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism

Garcia-Diaz, A., Blok, C., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2008). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1188-1190. doi:10.1093/jac/dkn374

DOI
10.1093/jac/dkn374
Journal article

<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure

Ochong, E., Bell, D. J., Johnson, D. J., D'Alessandro, U., Mulenga, M., Muangnoicharoen, S., . . . Owen, A. (2008). <i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 3883-3888. doi:10.1128/AAC.00431-08

DOI
10.1128/AAC.00431-08
Journal article

Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir

Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304

DOI
10.1086/592304
Journal article

Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir

Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320

DOI
10.1038/bjp.2008.320
Journal article

Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex

Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex. Molecular Pharmacology, 73(5), 1347-1355. doi:10.1124/mol.108.045120

DOI
10.1124/mol.108.045120
Journal article

Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex

Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex. MOLECULAR PHARMACOLOGY, 73(5), 1347-1355. doi:10.1124/mol.108.045120

DOI
10.1124/mol.108.045120
Journal article

Pharmacogenetics of antiretroviral agents

Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4

DOI
10.1097/COH.0b013e3282f7cda4
Journal article

Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors

Johnson, D. J., Owen, A., Plant, N., Bray, P. G., & Ward, S. A. (2008). Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(4), 1438-1445. doi:10.1128/AAC.01392-07

DOI
10.1128/AAC.01392-07
Journal article

Impact of <i>CYP2B6</i> 983T&gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T&gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029

DOI
10.1093/jac/dkn029
Journal article

Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells

Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. BRITISH JOURNAL OF PHARMACOLOGY, 153(4), 805-819. doi:10.1038/sj.bjp.0707601

DOI
10.1038/sj.bjp.0707601
Journal article

Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>.

Biagini, G. A., Fisher, N., Berry, N., Stocks, P., Meunier, B., Bray, P. G., . . . Ward, S. A. (2008). Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>.. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S41). Retrieved from https://www.webofscience.com/

Conference Paper

Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors?

Johnson, D. J., Owen, A., Plant, N., & Ward, S. A. (2008). Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors?. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S39). Retrieved from https://www.webofscience.com/

Conference Paper

Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs

Chaikan, A., Chierakul, N., Saguenwong, N., Chuchuttaworn, C., Owen, A., Dickinson, L., . . . Davies, G. R. (2008). Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. In Journal of the International AIDS Society Vol. 11 (pp. P237). Wiley. doi:10.1186/1758-2652-11-s1-p237

DOI
10.1186/1758-2652-11-s1-p237
Conference Paper

Lopinavir is a substrate for SLCO1A2 but 516A&gt;C and 38T&gt;C polymorphisms do not influence lopinavir plasma concentrations

Shallcross, V., Kwan, W. S., Hartkoorn, R., Mahungu, T., Khoo, S. H., Back, D. J., & Owen, A. (2008). Lopinavir is a substrate for SLCO1A2 but 516A&gt;C and 38T&gt;C polymorphisms do not influence lopinavir plasma concentrations. Journal of the International AIDS Society, 11(Suppl 1), P238. doi:10.1186/1758-2652-11-s1-p238

DOI
10.1186/1758-2652-11-s1-p238
Journal article

O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya

Kigen, G. K., Kimaiyo, S., Back, D. J., Gibbons, S. E., Sang, E., Edwards, I. G., . . . Khoo, S. H. (2008). O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya. Journal of the International AIDS Society, 11(Suppl 1), O7. doi:10.1186/1758-2652-11-s1-o7

DOI
10.1186/1758-2652-11-s1-o7
Journal article

Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C&gt;T SNP in the PXR gene

Siccardi, M., D'Avolio, A., Baietto, L., Calcagno, A., Gibbons, S. E., Sciandra, M., . . . Owen, A. (2008). Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C&gt;T SNP in the PXR gene. Journal of the International AIDS Society, 11(Suppl 1), P233. doi:10.1186/1758-2652-11-s1-p233

DOI
10.1186/1758-2652-11-s1-p233
Journal article

TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i>

Ochong, E., Salcedo, E., Bray, P., Ward, S., & Owen, A. (2008). TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i>. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 79 (pp. 302). Retrieved from https://www.webofscience.com/

Conference Paper

2007

Tacrine-induced liver damage: an analysis of 19 candidate genes

Alfirevic, A., Mills, T., Carr, D., Barratt, B. J., Jawaid, A., Sherwood, J., . . . Pirmohamed, M. (2007). Tacrine-induced liver damage: an analysis of 19 candidate genes. PHARMACOGENETICS AND GENOMICS, 17(12), 1091-1100. doi:10.1097/FPC.0b013e3282f1f12b

DOI
10.1097/FPC.0b013e3282f1f12b
Journal article

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353

DOI
10.1093/jac/dkm353
Journal article

Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification

Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281

DOI
10.1093/jac/dkm281
Journal article

Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects

Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230

DOI
10.1093/jac/dkm230
Journal article

Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>

Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/

Journal article

Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene

Kitteringham, N. R., Palmer, L., Owen, A., Lian, L. -Y., Jenkins, R., Dowdall, S., . . . Goldring, C. E. (2007). Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1770(8), 1240-1247. doi:10.1016/j.bbagen.2007.05.001

DOI
10.1016/j.bbagen.2007.05.001
Journal article

Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein

Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001

DOI
10.1016/j.tube.2006.12.001
Journal article

Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART

Liptrott, N., Mahungu, T., Youle, M., Johnson, M., Smith, C., Back, D., . . . Owen, A. (2007). Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 452. Retrieved from http://www.retroconference.org/2007/Abstracts/29534.htm

Journal article

TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure

Hartkoorn, R., Chandler, B., Owen, A., Ward, S., Squire, B., Back, D., & Khoo, S. (2007). TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 854. Retrieved from http://www.retroconference.org/2007/Abstracts/28849.htm

Journal article

The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics

Mahungu, T., Khoo, S., Smith, C., Youle, M., Johnson, M., Back, D., & Owen, A. (2007). The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 552. Retrieved from http://www.retroconference.org/2007/Abstracts/28960.htm

Journal article

2006

Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug

Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189

DOI
10.1136/ard.2005.049189
Journal article

Pharmacogenetics of HIV therapy

Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57

DOI
10.1097/01.fpc.0000236338.41799.57
Journal article

The impact of host pharmacogenetics on antiretroviral drug disposition.

Owen, A. (2006). The impact of host pharmacogenetics on antiretroviral drug disposition.. Current infectious disease reports, 8(5), 401-408. doi:10.1007/s11908-006-0052-2

DOI
10.1007/s11908-006-0052-2
Journal article

Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements

Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2006). Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 62(2), 237-242. doi:10.1111/j.1365-2125.2006.02587.x

DOI
10.1111/j.1365-2125.2006.02587.x
Journal article

Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance

Leschziner, G., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. PHARMACOGENETICS AND GENOMICS, 16(6), 439-450. doi:10.1097/01.fpc.0000197467.21964.67

DOI
10.1097/01.fpc.0000197467.21964.67
Journal article

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006

DOI
10.2165/00003088-200645020-00006
Journal article

Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes

Goldring, C. E. P., Kitteringham, N. R., Jenkins, R., Lovatt, C. A., Randle, L. E., Abdullah, A., . . . Park, B. K. (2006). Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 290(1), C104-C115. doi:10.1152/ajpcell.00133.2005

DOI
10.1152/ajpcell.00133.2005
Journal article

Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance

Leschziner, G. D., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenetics and Genomics, 16(6), 439-450.

Journal article

Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin

Martin, P., Riley, R., Khoo, S., Back, D., & Owen, A. (2006). Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 567.

Journal article

Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6

Owen, A., Cook, C., Liptrott, N., Khoo, S., & Back, D. (2006). Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 765.

Journal article

The assessment of multi-locus gene effects upon lopinavir pharmacokinetics

Owen, A., Mahungu, T., Cook, C., Youle, M., Johnson, M., Back, D., & Khoo, S. (2006). The assessment of multi-locus gene effects upon lopinavir pharmacokinetics. Eighth International Congress on Drug Therapy in HIV Infection, November, Glasgow, UK., N/A, Abstract PL5.4.

Journal article

2005

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40

DOI
10.1097/01.aids.0000194793.36175.40
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

DOI
10.1124/jpet.105.086272
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

DOI
10.1124/jpet.105.086272
Journal article

The implications of P-glycoprotein in HIV: friend or foe?

Owen, A., Chandler, B., & Back, D. J. (2005). The implications of P-glycoprotein in HIV: friend or foe?. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 19(3), 283-296. doi:10.1111/j.1472-8206.2005.00324.x

DOI
10.1111/j.1472-8206.2005.00324.x
Journal article

Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver

Owen, A., Goldring, C., Morgan, P., Chadwick, D., Park, B. K., & Pirmohamed, M. (2005). Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 59(3), 365-370. doi:10.1111/j.1365-2125.2005.02229.x

DOI
10.1111/j.1365-2125.2005.02229.x
Journal article

Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals

Chandler, B., Khoo, S., Detsika, M., Walsh, T., Williams, J., Back, D., & Owen, A. (2005). Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 665.

Journal article

Host determinants of antiretroviral drug activity

Boffito, M., Alan, W., & Owen, A. (2005). Host determinants of antiretroviral drug activity. CURRENT OPINION IN INFECTIOUS DISEASES, 18(6), 543-549. doi:10.1097/01.qco.0000191507.48481.10

DOI
10.1097/01.qco.0000191507.48481.10
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.

Journal article

Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines

Martin, P., Owen, A., Back, D., & Riley, R. (2005). Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines. DMDG Open Meeting, N/A(7-9 Se), N/A.

Journal article

Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes

Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2005). Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes. Toxicology, 213(3), 261-262.

Journal article

Mitochondria are sensors for HIV drugs

Petit, F., Fromenty, B., Owen, A., & Estaquier, J. (2005). Mitochondria are sensors for HIV drugs. TRENDS IN PHARMACOLOGICAL SCIENCES, 26(5), 258-264. doi:10.1016/j.tips.2005.03.006

DOI
10.1016/j.tips.2005.03.006
Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458

Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

Journal article

P-Glycoprotein and MRP1 Interactions with Rifampicin

Hartkoorn, R., Waitt, C., Chaponda, M., Davies, G., Chandler, B., Owen, A., . . . Khoo, S. (2005). P-Glycoprotein and MRP1 Interactions with Rifampicin. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 666.

Journal article

Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype

Owen, A., Almond, L., Hartkoorn, R., Walsh, T., Youle, M., Bonington, A., . . . Khoo, S. (2005). Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 650.

Journal article

The Implications of P-glycoprotein: Friend or Foe?

Owen, A., Chandler, B., & Back, D. (2005). The Implications of P-glycoprotein: Friend or Foe?. Fundamentals of Clinical Pharmacology, 19, 238-296.

Journal article

The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals

Dickinson, L., Back, D., Chandler, B., Owen, A., Khoo, S., Pozniak, A., & Boffito, M. (2005). The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. 6th International Workshop on Clinical Pharmacology of HIV Therapy, N/A(April), Abstract 9.

Journal article

2004

Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4

Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004

DOI
10.1128/JVI.78.21.12022-12029.2004
Journal article

Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA

Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/

Journal article

MULTI DRUG RESISTANCE PUMP (P-GLYCOPROTEIN) EXPRESSION IN PERIPHERAL BLOOD OF HEART TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH REJECTION.

Thekkudan, J., Fildes, J., Guntamadugu, R., Owen, A., Walker, A., Datta, S., . . . Leonard, C. (2004). MULTI DRUG RESISTANCE PUMP (P-GLYCOPROTEIN) EXPRESSION IN PERIPHERAL BLOOD OF HEART TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH REJECTION.. Transplantation, 78, 426. doi:10.1097/00007890-200407271-01141

DOI
10.1097/00007890-200407271-01141
Journal article

Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression

Singh, D., Alexander, J., Owen, A., Rustom, R., Bone, M., Hammad, A., . . . Pirmohamed, M. (2004). Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. TRANSPLANTATION, 77(4), 557-561. doi:10.1097/01.TP.0000114594.21317.A5

DOI
10.1097/01.TP.0000114594.21317.A5
Journal article

P-glycoprotein and outcome following lung transplantation

Fildes, J. E., Thekkudan, J., Guntamadugu, R., Owen, A., Singh, D., Yonan, N., & Leonard, C. T. (2004). P-glycoprotein and outcome following lung transplantation. The Journal of Heart and Lung Transplantation, 23(2), S166. doi:10.1016/j.healun.2003.11.370

DOI
10.1016/j.healun.2003.11.370
Journal article

-glycoprotein and outcome following lung transplantation

Fildes, J. E., Thekkudan, J., Guntamadugu, R., Owen, A., Singh, D., Yonan, N., & Leonard, C. T. (2004). -glycoprotein and outcome following lung transplantation. The International Society for Heart and Lung Transplantation 24th Annual Meeting and Scientific Sessions, N/A(21-24), N/A.

Journal article

Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells

Chandler, B., Owen, A., Bray, P. G., Ward, S. A., Back, D. J., & Khoo, S. H. (2004). Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells. XV International AIDS Conference, N/A(11-18), N/A.

Journal article

Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype

Owen, A., Chandler, B., Walsh, T., Williams, J., Penny, M., Back, D., & Khoo, S. (2004). Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype. Meeting on Pharmacogenomics, N/A(Novemb), 90.

Journal article

Detection of Minority Strains of HIV Harbouring Drug Resistance

Detsika, M., Winstanley, C., Owen, A., Cane, P., Khoo, S., Back, D., & Hart, C. (2004). Detection of Minority Strains of HIV Harbouring Drug Resistance. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, N/A(30 Oct), N/A.

Journal article

Development of doxycycline-regulatable gene expression in hepatoma cells

Goldring, C., Kitteringham, N., Lovatt, C., Jenkins, R., Randle, L., Abdullah, A., . . . Park, K. (2004). Development of doxycycline-regulatable gene expression in hepatoma cells. Joint meeting of the BPS/BTS. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.

Journal article

Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype

Chandler, B., Owen, A., Back, D. J., & Khoo, S. H. (2004). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.

Journal article

Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents

Janneh, O., Owen, A., Hartkoorn, R. C., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents. BSAC Spring Meeting 2004 in collaboration with the Society of Pharmaceutical Medicine, N/A(2-3 Ma), N/A.

Journal article

Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1

Owen, A., Chandler, B., Back, D., & Khoo, S. H. (2004). Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1. Antiviral Therapy, 9(5), 819-821.

Journal article

Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs

Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs. Microsomes and Drug Oxidations, N/A(4-9 Ju), N/A.

Journal article

Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4

Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.

Journal article

In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein

Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein. XV International AIDS Conference, N/A(11-18), N/A.

Journal article

Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes

Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2004). Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.

Journal article

Intracellular pharmacokinetics of antiretroviral agents.

Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.

Journal article

Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters

Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.

Journal article

The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study

Owen, A., Fox, Z., Almond, L., Dragsted, U. B., Youle, M., Lundgren, J., . . . On behalf of the MaxCmin1 Steering Committee. (2004). The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.

Journal article

The interaction between active drug transporters and rifampicin accumulation

Hartkoorn, R. C., Janneh, O., Owen, A., Davies, G. R., Chandler, R. J., Khoo, S., & Back, D. J. (2004). The interaction between active drug transporters and rifampicin accumulation. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.

Journal article

2003

Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines

Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024

DOI
10.1097/00002030-200310170-00024
Journal article

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro

Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001

DOI
10.1097/00126334-200308150-00001
Journal article

A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets

Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4

DOI
10.1016/S0022-1759(02)00509-4
Journal article

Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells

Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902

DOI
10.1086/367902
Journal article

The mechanisms that control intracellular penetration of the HIV protease inhibitors

Hoggard, P. G., & Owen, A. (2003). The mechanisms that control intracellular penetration of the HIV protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 51(3), 493-496. doi:10.1093/jac/dkg137

DOI
10.1093/jac/dkg137
Journal article

A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets

Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539

Journal article

Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells.

Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells.. Journal of Infectious Diseases, 18(5), 874-875.

Journal article

Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype

Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2003). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.

Journal article

Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression

Owen, A., Park, B. K., & Pirmohamed, M. (2003). Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.

Journal article

Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes

Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2003). Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, N/A(July 8), N/A.

Journal article

Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect

Owen, A., Janneh, O., Hartkoorn, R., Chandler, R., Back, D. J., & Khoo, S. H. (2003). Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect. Federation of Infection Societies Tenth Anniversary Conference, N/A(Novemb), N/A.

Journal article

The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers

Maher, B., Hoggard, P. G., Chandler, B., Meaden, E. R., Owen, A., Back, D. J., . . . Pirmohamed, M. (2003). The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 524a.

Journal article

The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics.

Owen, A., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics.. 8th European ISSX meeting, N/A(Apr 27), Abstract 307.

Journal article

The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines.

Owen, A., Hoggard, P. G., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines.. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 149.

Journal article

The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.

Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S. H., & Back., D. J. (2003). The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.. Journal of Acquired Immune Deficiency Syndromes, 33(5), 551-556.

Journal article

2002

Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing

Almond, L. M., Chandler, B., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2002). Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing. XIV International AIDS conference, N/A(7-12 J), N/A.

Journal article

In-vitro Antiretroviral Activity of Antimalarial Agents.

Owen, A., Hoggard, P. G., Bray, P. G., Ward, S. A., Khoo, S. H., Hart, C. A., & Back, D. J. (2002). In-vitro Antiretroviral Activity of Antimalarial Agents.. Sixth International Congress on Drug Therapy in HIV Infection, N/A(17-21), N/A.

Journal article

Induction of P-glycoprotein in PBMCs in vitro

Chandler, B., Ford, J., Owen, A., Khoo, S. H., & Back, D. J. (2002). Induction of P-glycoprotein in PBMCs in vitro. XIV International AIDS conference, N/A(7-12 J), N/A.

Journal article

Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression

Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2002). Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.

Journal article

The role of drug transporters in HIV treatment failure

Owen, A., Hoggard, P. G., & Khoo, S. (2002). The role of drug transporters in HIV treatment failure. HIV and AIDS current trends, 8, 11-12.

Journal article

2001

LC determination of carbamazepine in murine brain

Owen, A., Tettey, J. N., Morgan, P., Pirmohamed, M., & Park, B. K. (2001). LC determination of carbamazepine in murine brain. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 26(4), 573-577. doi:10.1016/S0731-7085(01)00477-0

DOI
10.1016/S0731-7085(01)00477-0
Journal article

Carbamazepine is not a substrate for P-glycoprotein

Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2001). Carbamazepine is not a substrate for P-glycoprotein. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 345-349. doi:10.1046/j.1365-2125.2001.01359.x

DOI
10.1046/j.1365-2125.2001.01359.x
Journal article

2000

Is Carbamazepine a Substrate for P-glycoprotein?

Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is Carbamazepine a Substrate for P-glycoprotein?. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.

Journal article

Is carbamezapine a substrate for P-glycoprotein?

Owen, A., Pirmohamed, M., Tettey, J., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is carbamezapine a substrate for P-glycoprotein?. In British Journal of Clinical Pharmacology Vol. 50 (pp. 387).

Conference Paper

1999

Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy

Owen, A., Pirmohamed, M., Morgan, P., Chadwick, D., & Park, B. K. (1999). Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy. Pfizer Poster Symposium, N/A(N/A), N/A.

Journal article